TWD
GLUE icon

True Wealth Design’s Monte Rosa Therapeutics GLUE Stock Holding History

True Wealth Design’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03K Sell
84
-7
-8% -$132 ﹤0.01% 1686
2026
Q1 		$1.5K Sell
91
-20
-18% -$382 ﹤0.01% 1656
2025
Q4 		$1.74K Buy
111
+27
+32% +$364 ﹤0.01% 1503
2025
Q3 		$623 Buy
84
+42
+100% +$222 ﹤0.01% 1936
2025
Q2 		$190 Buy
42
+19
+83% +$85 ﹤0.01% 2090
2025
Q1 		$107 Buy
+23
New +$141 ﹤0.01% 2168

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

True Wealth Design's GLUE Position: Q2 2026 in Review

True Wealth Design reduced its Monte Rosa Therapeutics (GLUE) stake by 7.7% in Q2 2026, selling an estimated $132 and leaving 84 shares worth $2.03K. The position accounts for ﹤0.01% of the portfolio, ranked #1686.

True Wealth Design first reported a position in GLUE in Q1 2025 and has held it in 6 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • True Wealth Design held 84 shares of Monte Rosa Therapeutics worth $2.03K as of Q2 2026.
  • True Wealth Design sold 7 Monte Rosa Therapeutics shares in Q2 2026, an estimated $132.
  • Monte Rosa Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1686 holding.
  • True Wealth Design first reported a position in Monte Rosa Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.